| Not Yet Recruiting | Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For NCT07444632 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma NCT07514819 | St. Jude Children's Research Hospital | N/A |
| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | CD45BE-HSPC + CART-45 Cells NCT07451054 | University of Pennsylvania | Phase 1 |
| Not Yet Recruiting | Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin NCT07222345 | St. Jude Children's Research Hospital | N/A |
| Not Yet Recruiting | Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study NCT07292272 | University of Nebraska | Phase 2 |
| Not Yet Recruiting | PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma NCT07256158 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Not Yet Recruiting | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell NCT07164469 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Prognostic Model of Elderly Hodgkin Lymphoma in China NCT07374068 | Tianjin Medical University Cancer Institute and Hospital | — |
| Recruiting | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690 | Baylor College of Medicine | Phase 1 |
| Recruiting | Mozobil for Autologous Hematopoietic Stem Cell Transplantation NCT07188090 | Thomas Jefferson University | Phase 2 |
| Not Yet Recruiting | Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma NCT06045195 | University of Cologne | Phase 2 |
| Recruiting | PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma NCT07209059 | National Research Center for Hematology, Russia | Phase 2 |
| Recruiting | Genetic Markers of Susceptibility to Chemotherapy-induced Ovarian Damage in Cancer Patients Undergoing Ovarian NCT07270679 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin NCT06383338 | Murdoch Childrens Research Institute | Phase 1 |
| Recruiting | BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma NCT07002216 | University of Miami | Phase 2 |
| Recruiting | A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma NCT06915246 | VIVUS LLC | Phase 2 |
| Active Not Recruiting | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer NCT06521567 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Recruiting | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis NCT06680661 | Leland Metheny | Phase 2 |
| Active Not Recruiting | Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients Wit NCT06744075 | Centre Henri Becquerel | N/A |
| Recruiting | Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL NCT07234487 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral NCT06398457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Terminated | Impact of Respiratory Training in Lymphoma Survivors NCT05938127 | University of Colorado, Denver | N/A |
| Recruiting | PD-1 Inhibitors Maintenance for cHL Post-autoHCT NCT06812858 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma i NCT06831370 | Takeda | Phase 4 |
| Recruiting | Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing NCT06550427 | National Taiwan University Hospital | — |
| Recruiting | Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refracto NCT06733987 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Recruiting | PTCy and ATG for MSD and MUD Transplants NCT06299462 | Instituto Nacional de Cancer, Brazil | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standar NCT05977673 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Recruiting | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells NCT06090864 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma NCT06377566 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies NCT06150664 | Compass Therapeutics | Phase 1 |
| Not Yet Recruiting | Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lY NCT05627115 | University College, London | Phase 2 |
| Active Not Recruiting | Integrated Actionable Aging Assessment for Cancer Patients Pilot NCT05871008 | University of Colorado, Denver | N/A |
| Active Not Recruiting | Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma NCT06761599 | Superior University | — |
| Recruiting | AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haem NCT06137144 | AstraZeneca | Phase 1 / Phase 2 |
| Completed | Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma NCT06564259 | Tishreen University | — |
| Withdrawn | A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin NCT06104878 | Takeda | — |
| Recruiting | A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patient NCT06170489 | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 |
| Active Not Recruiting | PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic H NCT05922904 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors NCT06002828 | ECOG-ACRIN Cancer Research Group | — |
| Active Not Recruiting | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Pat NCT05502250 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Recruiting | The Pathogenesis and Prognostic Factors of Lymphoma NCT06203652 | Shanghai Zhongshan Hospital | — |
| Recruiting | Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymp NCT05723055 | University of Utah | Phase 2 |
| Not Yet Recruiting | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation NCT03969693 | Chang Gung Memorial Hospital | — |
| Recruiting | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NCT05615636 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Lifestyle Intervention of Food and Exercise for Lymphoma Survivors NCT05839210 | University of Miami | N/A |
| Unknown | Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma NCT05757466 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Improving Exercise Capacity With a Tailored Physical Activity Intervention NCT05595577 | Wake Forest University Health Sciences | N/A |
| Active Not Recruiting | Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childho NCT05550948 | St. Jude Children's Research Hospital | N/A |
| Recruiting | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma NCT05798897 | Marker Therapeutics, Inc. | Phase 1 |
| Unknown | Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients NCT05663983 | Campus Bio-Medico University | — |
| Recruiting | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation NCT04935684 | University Hospital, Clermont-Ferrand | Phase 2 |
| Terminated | First in Human, Dose Escalation, Dose Expansion Study of AUR105 NCT05605119 | Aurigene Discovery Technologies Limited | Phase 1 |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Recruiting | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma NCT05180097 | Canadian Cancer Trials Group | Phase 2 |
| Recruiting | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphod NCT05092451 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma NCT05595447 | Hospital Regional de Alta Especialidad del Bajio | Phase 2 / Phase 3 |
| Completed | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1 NCT05508867 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | BV-AVD-R Treatment Children Hodgkin's Lymphoma NCT06201507 | Beijing Children's Hospital | Phase 2 |
| Completed | Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial NCT05205512 | City of Hope Medical Center | N/A |
| Suspended | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122 | David Wald | Phase 1 |
| Recruiting | A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma NCT05481437 | Takeda | — |
| Completed | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors NCT05131815 | Cedars-Sinai Medical Center | N/A |
| Unknown | Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma NCT05490953 | University of Guadalajara | Phase 4 |
| Active Not Recruiting | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma NCT04788043 | Stanford University | Phase 2 |
| Completed | MargheRITA (Remote Intelligence for Therapeutic Adherence) NCT05260203 | Advice Pharma Group srl | N/A |
| Unknown | Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs NCT05284396 | Assiut University | — |
| Recruiting | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma NCT04685616 | University College, London | Phase 3 |
| Recruiting | A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma NCT05100056 | Takeda | — |
| Recruiting | Investigating Cognitive Impairment in Young Patients With Cancer Prospectively NCT05840575 | Rigshospitalet, Denmark | — |
| Terminated | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplant NCT05181540 | Angiocrine Bioscience | Phase 3 |
| Withdrawn | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiova NCT05169151 | M.D. Anderson Cancer Center | — |
| Recruiting | Early Ageing During Therapy in AYA Cancer Patients NCT05062707 | University Medical Center Groningen | — |
| Unknown | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD3 NCT05208853 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma NCT05253495 | New York Medical College | Phase 2 |
| Unknown | Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients NCT05254821 | Federico II University | — |
| Recruiting | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors NCT07259304 | University of Southern California | — |
| Completed | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy NCT05065866 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma NCT05019976 | University of Chicago | N/A |
| Completed | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study NCT05053100 | Mayo Clinic | — |
| Completed | Lung Screening in People Cured of Hodgkin Lymphoma NCT04986189 | The Christie NHS Foundation Trust | N/A |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Completed | Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events NCT05123001 | Stanford University | — |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL NCT04938232 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma NCT04996862 | The Christie NHS Foundation Trust | — |
| Unknown | A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advance NCT04843267 | Sun Yat-sen University | Phase 2 |
| Terminated | Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical NCT04621604 | Rennes University Hospital | N/A |
| Recruiting | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depl NCT04099966 | Mitchell Cairo | Phase 2 |
| Recruiting | Radiation Free Chemotherapy for Early Hodgkin Lymphoma NCT04866654 | Medical University of Gdansk | Phase 2 |
| Unknown | A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Ca NCT04981899 | St. Petersburg State Pavlov Medical University | Phase 1 / Phase 2 |
| Unknown | Methods of T Cell Depletion Trial (MoTD) NCT04888741 | University of Birmingham | Phase 2 |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Completed | Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With He NCT04748185 | Mayo Clinic | — |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers NCT04072393 | Washington University School of Medicine | N/A |
| Unknown | Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma NCT04893538 | Tishreen University | — |
| Active Not Recruiting | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study NCT04537871 | City of Hope Medical Center | — |
| Withdrawn | Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma NCT04373083 | Regeneron Pharmaceuticals | Phase 2 |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer NCT04666025 | City of Hope Medical Center | — |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Unknown | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody R NCT04514081 | Chinese PLA General Hospital | Phase 2 |
| Completed | Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transp NCT04478123 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma NCT04419441 | Ospedale Maggiore Di Trieste | — |
| Completed | Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial NCT05066555 | Fondazione Italiana Linfomi - ETS | — |
| Completed | Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHA NCT04091490 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Phase 2 |
| Completed | Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study NCT04396119 | The Christie NHS Foundation Trust | — |
| Unknown | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Re NCT04233294 | Chinese PLA General Hospital | Phase 2 |
| Unknown | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma NCT04239170 | Peking University | Phase 2 |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277 | City of Hope Medical Center | Phase 2 |
| Terminated | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing P NCT03947255 | Seagen Inc. | Phase 2 |
| Unknown | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study NCT03617666 | University College, London | Phase 2 |
| Unknown | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin NCT04510610 | Chinese PLA General Hospital | Phase 2 / Phase 3 |
| Recruiting | Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin NCT06883604 | Uppsala University Hospital | N/A |
| Unknown | Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, V NCT05660993 | National Research Center for Hematology, Russia | Phase 2 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen NCT04026269 | Han weidong | Phase 1 / Phase 2 |
| Unknown | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies NCT04008394 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Active Not Recruiting | Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma NCT03843294 | Catherine Bollard | Phase 1 |
| Unknown | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) NCT04025424 | Russian Academy of Medical Sciences | — |
| Completed | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) NCT03904134 | Center for International Blood and Marrow Transplant Research | N/A |
| Completed | Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx NCT03923504 | Virginia Commonwealth University | N/A |
| Completed | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation NCT03925935 | Angiocrine Bioscience | Phase 1 |
| Completed | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas NCT03894618 | Shattuck Labs, Inc. | Phase 1 |
| Completed | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies NCT03885947 | Alla Keyzner | Phase 1 |
| Recruiting | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Red NCT03852407 | University of Liege | Phase 2 |
| Active Not Recruiting | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in NCT03849651 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma NCT03646123 | Seagen Inc. | Phase 2 |
| Active Not Recruiting | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Unknown | Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma NCT03602131 | Sichuan University | Phase 2 |
| Completed | Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma NCT03730363 | Reinhold Munker | Phase 1 |
| Active Not Recruiting | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 NCT03755804 | St. Jude Children's Research Hospital | Phase 2 |
| Active Not Recruiting | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma NCT03337919 | University College, London | Phase 2 |
| Withdrawn | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344 | City of Hope Medical Center | Phase 2 |
| Unknown | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma NCT03331731 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Completed | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT03739619 | Emory University | Phase 1 / Phase 2 |
| Completed | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoi NCT03734601 | Stanford University | Phase 2 |
| Terminated | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS NCT03495713 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Recruiting | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma NCT03681561 | Veronika Bachanova | Phase 1 / Phase 2 |
| Completed | Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma NCT03580408 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma NCT03302728 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Completed | CBT on Fatigue in Survivors of Hodgkin Lymphoma NCT03968250 | University of Leipzig | N/A |
| Active Not Recruiting | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Tran NCT03560752 | City of Hope Medical Center | Phase 1 |
| Unknown | BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) NCT03576378 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 1 / Phase 2 |
| Recruiting | Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma NCT03618550 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors NCT03615105 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and C NCT03524235 | Noah Merin | Phase 1 |
| Completed | Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progres NCT03436862 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma NCT03505996 | CStone Pharmaceuticals | Phase 2 |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Active Not Recruiting | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (M NCT03407144 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma NCT04726501 | Children's Cancer Group, China | Phase 4 |
| Unknown | BV After Allogeneic Hematopoietic Stem Cell Transplantation NCT03540849 | University Hospital, Caen | Phase 2 |
| Completed | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation NCT03434730 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma NCT03664323 | Hospices Civils de Lyon | — |
| Active Not Recruiting | Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation NCT03361020 | St. Jude Children's Research Hospital | — |
| Unknown | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy NCT03527628 | King Abdullah International Medical Research Center | Phase 2 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | To Decrease Fatigue With Light Therapy NCT03242902 | The Netherlands Cancer Institute | Phase 3 |
| Unknown | SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma NCT03250962 | Chinese PLA General Hospital | Phase 2 |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | FIL Study on ABVD DD-DI as Upfront Therapy in HL. NCT03159897 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Completed | Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lympho NCT03343665 | St. Petersburg State Pavlov Medical University | Phase 1 / Phase 2 |
| Completed | ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma NCT03107663 | ImaginAb, Inc. | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymph NCT03179917 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Auto Stem Cell Transplant for Lymphoma Patients NCT03125642 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma NCT03120676 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Recruiting | Bergamo Lymphoid Cancer Registry NCT03131531 | A.O. Ospedale Papa Giovanni XXIII | — |
| Unknown | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas NCT03383965 | Immune Cell, Inc. | Phase 1 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT NCT03018223 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL NCT03033914 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery NCT02955043 | University of Wisconsin, Madison | N/A |
| Withdrawn | Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant NCT02115126 | David Rizzieri, MD | Phase 2 |
| Completed | Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure NCT03323541 | University Hospital, Brest | — |
| Terminated | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas NCT02763254 | Cell Medica Ltd | Phase 2 |
| Completed | Genetic Study of Families With High Frequency of Hodgkin Lymphoma NCT02795013 | St. Jude Children's Research Hospital | — |
| Terminated | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) NCT02624388 | University of Virginia | Phase 2 |
| Unknown | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool NCT02791217 | Assuta Medical Center | — |
| Completed | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical NCT02684292 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin NCT02665650 | Affimed GmbH | Phase 1 |
| Completed | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVAL NCT02973113 | Baylor College of Medicine | Phase 1 |
| Recruiting | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and S NCT02508038 | University of Wisconsin, Madison | Phase 1 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV a NCT02506933 | City of Hope Medical Center | Phase 2 |
| Terminated | Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Ly NCT02624258 | University of Pennsylvania | EARLY_Phase 1 |
| Completed | A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma NCT02572167 | Seagen Inc. | Phase 1 / Phase 2 |
| Completed | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma NCT02432235 | ADC Therapeutics S.A. | Phase 1 |
| Unknown | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies NCT02507479 | Sheba Medical Center | Phase 2 |
| Completed | Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphom NCT02191930 | University of Cologne | Phase 2 |
| Completed | Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma NCT02505269 | Massachusetts General Hospital | Phase 2 |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-34 NCT02453594 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia NCT02473523 | St. Jude Children's Research Hospital | N/A |
| Completed | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Tr NCT02424968 | Robert Lowsky | Phase 2 |
| Completed | GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgki NCT02321592 | University of Cologne | Phase 2 |
| Completed | Brentuximab for Newly Diagnosed Hodgkin Disease NCT02398240 | Mitchell Cairo | Phase 2 |
| Completed | Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymp NCT02429375 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL NCT02362997 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycle NCT02298283 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. NCT02292979 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Completed | Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastin NCT03480087 | A.O.U. Città della Salute e della Scienza | — |
| Completed | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies NCT02566395 | Northwell Health | Phase 3 |
| Completed | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Tr NCT02129582 | Case Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer NCT02256137 | St. Jude Children's Research Hospital | — |
| Completed | Detection and Characterization of Residual Masses in Lymphomas NCT02300402 | The Lymphoma Academic Research Organisation | — |
| Terminated | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors NCT02080416 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Unknown | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hod NCT02280993 | Marjolein Spiering | Phase 1 |
| Completed | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma NCT01990534 | Millennium Pharmaceuticals, Inc. | Phase 4 |
| Unknown | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ NCT02098512 | New York Medical College | Phase 1 / Phase 2 |
| Completed | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) NCT01953692 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplant NCT01634217 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lym NCT01950364 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies NCT01998035 | Columbia University | Phase 1 / Phase 2 |
| Completed | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies NCT01947140 | Jennifer Amengual | Phase 1 / Phase 2 |
| Completed | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma NCT01943682 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Completed | Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for P NCT06295211 | Federico II University | — |
| Completed | Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractor NCT01900509 | St. Jude Children's Research Hospital | Phase 1 |
| Terminated | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms NCT01908387 | Celgene Corporation | Phase 1 |
| Completed | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diag NCT01793233 | Children's Oncology Group | — |
| Withdrawn | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) NCT01652261 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Active Not Recruiting | Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable R NCT01868451 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation NCT01820117 | St. Jude Children's Research Hospital | — |
| Unknown | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma NCT02275598 | University of Modena and Reggio Emilia | Phase 2 |
| Completed | Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disea NCT02227433 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma NCT01712490 | Takeda | Phase 3 |
| Completed | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma NCT01569204 | University of Cologne | Phase 2 |
| Completed | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab NCT01592370 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01453504 | University of Cologne | Phase 1 / Phase 2 |
| Completed | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma NCT01657331 | Columbia University | Phase 1 / Phase 2 |
| Completed | BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology NCT01660776 | Rennes University Hospital | — |
| Completed | Double Cord Versus Haploidentical (BMT CTN 1101) NCT01597778 | Medical College of Wisconsin | Phase 3 |
| Completed | Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma NCT01534078 | Massachusetts General Hospital | Phase 2 |
| Completed | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases NCT01447056 | Baylor College of Medicine | Phase 1 |
| Completed | Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma NCT02247869 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | HD17 for Intermediate Stage Hodgkin Lymphoma NCT01356680 | University of Cologne | Phase 3 |
| Active Not Recruiting | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL NCT01333046 | Baylor College of Medicine | Phase 1 |
| Completed | Music Therapy on Nausea and Pain for Autologous Stem Cell NCT01487031 | Case Comprehensive Cancer Center | N/A |
| Withdrawn | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy NCT01452334 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma NCT01468311 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545 | Center for International Blood and Marrow Transplant Research | — |
| Completed | Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma NCT01393106 | Gilead Sciences | Phase 2 |
| Completed | Study of Lymphoma in Asia NCT01584141 | National Cancer Institute (NCI) | — |
| Unknown | IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma NCT01333605 | Fudan University | Phase 2 |
| Completed | Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma NCT01217229 | Daiichi Sankyo | Phase 2 |
| Completed | Screening for Coronary Artery Disease After Mediastinal Irradiation NCT01271127 | Leiden University Medical Center | N/A |
| Completed | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies NCT01263899 | S*BIO | Phase 2 |
| Completed | 124I-FIAU Imaging in EBV and KSHV Associated Cancers NCT00982449 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Withdrawn | Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following NCT01165645 | Mayo Clinic | N/A |
| Completed | A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) NCT01523847 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Active Not Recruiting | Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma NCT01231269 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Completed | A Study to Assess AFM13 in Patients With Hodgkin Lymphoma NCT01221571 | Affimed GmbH | Phase 1 |
| Completed | Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients NCT01056679 | University of Cologne | Phase 1 |
| Unknown | Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies NCT01079013 | Sheba Medical Center | Phase 2 |
| Completed | Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients NCT01228461 | Vanderbilt University | — |
| Completed | Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chem NCT01022996 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | HD16 for Early Stage Hodgkin Lymphoma NCT00736320 | University of Cologne | Phase 3 |
| Completed | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refracto NCT01030900 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Brazilian Prospective Hodgkin Lymphoma Registry NCT02589548 | Universidade Federal do Rio de Janeiro | — |
| Terminated | R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma NCT00992030 | Fondazione Michelangelo | Phase 3 |
| Completed | Proton Therapy for Hodgkin Lymphoma NCT00850200 | University of Florida | N/A |
| Active Not Recruiting | Methionine PET/CT Studies In Patients With Cancer NCT00840047 | St. Jude Children's Research Hospital | Phase 2 |
| Unknown | Gonadal Toxicity in Women With Hodgkin Lymphoma NCT01008735 | Gruppo Italiano Studio Linfomi | — |
| Active Not Recruiting | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodg NCT00846742 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Pr NCT00928018 | Dana-Farber Cancer Institute | Phase 3 |
| Completed | Unrelated Umbilical Cord Blood (UBC)Transplantation NCT01768845 | West Virginia University | N/A |
| Terminated | Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgki NCT00722865 | Massachusetts General Hospital | Phase 2 |
| Terminated | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma NCT00512980 | University of Cologne | Phase 2 |
| Completed | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT NCT00709592 | Virginia Commonwealth University | Phase 2 |
| Completed | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple My NCT00722488 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) NCT00795613 | Ospedale Santa Croce-Carle Cuneo | Phase 2 |
| Completed | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR NCT01611298 | Robert Krance | N/A |
| Completed | Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Mali NCT00566696 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma NCT00606645 | Xencor, Inc. | Phase 1 |
| Terminated | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE NCT00578539 | Baylor College of Medicine | N/A |
| Completed | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen NCT00556452 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Terminated | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgki NCT00543582 | Mirati Therapeutics Inc. | Phase 2 |
| Completed | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD NCT00539695 | Baylor College of Medicine | Phase 2 |
| Completed | Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma NCT00439361 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. NCT00392314 | Rambam Health Care Campus | Phase 2 |
| Terminated | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT NCT01220297 | Stanford University | Phase 2 |
| Unknown | Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma NCT00877747 | Ospedale Santa Croce-Carle Cuneo | — |
| Unknown | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haemat NCT00598624 | IRCCS San Raffaele | Phase 2 |
| Completed | Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients NCT01764230 | Masaryk University | N/A |
| Completed | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Ce NCT00096161 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Genome Expression in Lymphoma, Leukemia and Multiple Myeloma NCT00339963 | National Cancer Institute (NCI) | — |
| Completed | Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission NCT04298619 | Federico II University | — |